Centene accuses Celgene of delaying generic versions of Thalomid, Revlimid in US
MLex Summary: Centene filed a US complaint accusing Celgene and its owner, Bristol-Myers Squibb, of illegally monopolizing the market for Thalomid and Revlimid. The complaint claims Celgene has successfully interfered with...To view the full article, register now.
Already a subscriber? Click here to view full article